AVEO - 3.21 Pre-market now at 3.25/3.35 AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma http://stockcharts.com/c-sc/sc?s=AVEO&p=D&b=5&g=0&i=0&r=1509972766174 http://stockcharts.com/c-sc/sc?s=AVEO&p=W&b=5&g=0&i=t42047094518&r=1509972784777